Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
Early dose-limiting toxicities have prohibited the expansion of ADCs into larger and more complex tumour indications, dampening the initial hopes of a new “magic bullet” in the fight against cancer. tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs.
82 
Let's personalize your content